Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDE: Fluorescently Labeled Adalimumab-680LT in Inflammatory Bowel Disease
2023-508391-11-00Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease, sponsored by University Medical Center Groningen. Primary endpoint: Safety and feasibility of adalimumab-680LT and fluorescence molecular endoscopy. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2023-508391-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508391-11-00.